BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer
Completed
- Conditions
- Ovarian Cancer, Peritoneal Neoplasms
- Registration Number
- NCT01788995
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma). Newly diagnosed patients who are initiated on carboplatin/paclitaxel chemotherapy in combination with Avastin will be followed for up to 15 months of treatment and 12 months of follow-up.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 63
Inclusion Criteria
- Adult patients, >/= 18 years of age
- Patients with newly diagnosed advanced epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for first-line carboplatin/paclitaxel chemotherapy in combination with Avastin
Exclusion Criteria
- Contraindications for Avastin according to the Summary of Product Characteristics
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment discontinuations/modifications approximately 4 years Duration of treatment approximately 4 years Clinical/demographic patient characteristics at initiation of treatment approximately 4 years
- Secondary Outcome Measures
Name Time Method Progression-free survival approximately 4 years Safety: Incidence of adverse events approximately 4 years
Trial Locations
- Locations (1)
Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie
🇦🇹Innsbruck, Austria